Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marcel Bavoux

Internal Medicine Danielson, CT Doctor of Osteopathy

NPI 1508990557 CMS profile 68025

42 Reynolds St, Danielson, CT 06239

Open in the dashboard

General payments

$2,874

165 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marcel Bavoux of Danielson, CT is reported in the CMS Open Payments database as having received $2,874 across 165 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $518 20
2024 General $120 1
2022 General $18 1
2021 General $88 3
2020 General $390 19
2019 General $1,739 121

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marcel Bavoux
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Marcel Bavoux were reported at $518. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Marcel Bavoux Internal Medicine median Middle half National median
2019 $1,739 $159 $48–$570 $163
2020 $390 $119 $33–$402 $114
2021 $88 $135 $37–$521 $132
2022 $18 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $120 $154 $47–$537 $164
2025 $518 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $549 28 payments
  2. AbbVie, Inc. $399 19 payments
  3. Pfizer Inc. $337 31 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $182 9 payments
  5. Genentech USA, Inc. $140 6 payments
  6. Amgen Inc. $125 7 payments
  7. GlaxoSmithKline, LLC. $119 8 payments
  8. Teva Pharmaceuticals USA, Inc. $98 7 payments
  9. Sunovion Pharmaceuticals Inc. $91 7 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $88 5 payments
  11. Other $747 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,832 161 payments
  2. Education $42 4 payments
Products named General payments · program years 2019–2025
  1. COLOGUARD $260 24 payments
  2. FARXIGA $186 12 payments
  3. UBRELVY $180 6 payments
  4. SYMBICORT $150 11 payments
  5. AIRSUPRA $145 2 payments
  6. Xofluza $140 6 payments
  7. JARDIANCE $118 5 payments
  8. EVENITY $113 6 payments
  9. CREON $107 6 payments
  10. CHANTIX $105 14 payments
  11. Other $1,980 135 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 80 drugs

Part D claims

2,971

Median for Internal Medicine: 777

Drug cost

$277,762

Median for Internal Medicine: $73,373

Branded share of claims

21.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 52 $52,205
Eliquis Apixaban Brand 30 $38,952
Januvia Sitagliptin Phosphate Brand 22 $34,535
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 43 $27,794
Ozempic Semaglutide Brand 22 $25,455
Tradjenta Linagliptin Brand 20 $15,880
Trulicity Dulaglutide Brand 16 $15,227
Linzess Linaclotide Brand 14 $12,051
Incruse Ellipta Umeclidinium Bromide Brand 19 $8,008
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 47 $6,024

The 10 drugs with the highest cost, of 80 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $120
$120 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

165 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record